Literature DB >> 16036046

Disruptions and detours in the myocardial matrix highway and heart failure.

Anne M Deschamps1, Francis G Spinale.   

Abstract

Myocardial remodeling invariably occurs in congestive heart failure (CHF) and is a response to a prolonged cardiovascular stress, which is characterized by a cascade of compensatory structural events. Remodeling of the myocardial interstitium occurs in CHF and likely contributes to the progression of the remodeling process. The myocardial matrix can be considered a biological highway in which a large amount of signaling proteins and structural proteins are being moved within the interstitium, entering and exiting the interstitial space, and docking to cellular components. The rates at which these events occur can accelerate and decelerate depending on the particular cardiac disease state and thereby can alter the course of myocardial remodeling. Once considered merely a scaffolding to align cells, the matrix plays a complex and divergent role in influencing cell behavior. For example, the matrix has a functional role in cell migration, proliferation, adhesion, and cell-to-cell signaling. In light of this, the myocardial matrix should not be regarded as merely a static structure, but rather, as a complex system of dynamic interactions between matrix molecules, signaling proteins, and transmembrane proteins. Specific strategies that are targeted at modifying activity along this matrix highway will likely alter the course of myocardial remodeling and heart failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16036046     DOI: 10.1007/s11897-005-0002-6

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  75 in total

1.  Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.

Authors:  J T Peterson; H Li; L Dillon; J W Bryant
Journal:  Cardiovasc Res       Date:  2000-05       Impact factor: 10.787

2.  Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.

Authors:  C V Thomas; M L Coker; J L Zellner; J R Handy; A J Crumbley; F G Spinale
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

3.  The collagen network of the heart.

Authors:  J B Caulfield; T K Borg
Journal:  Lab Invest       Date:  1979-03       Impact factor: 5.662

4.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy.

Authors:  Masanori Asakura; Masafumi Kitakaze; Seiji Takashima; Yulin Liao; Fuminobu Ishikura; Tsuyoshi Yoshinaka; Hiroshi Ohmoto; Koichi Node; Kohichiro Yoshino; Hiroshi Ishiguro; Hiroshi Asanuma; Shoji Sanada; Yasushi Matsumura; Hiroshi Takeda; Shintaro Beppu; Michihiko Tada; Masatsugu Hori; Shigeki Higashiyama
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

5.  Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure.

Authors:  V S Mujumdar; S C Tyagi
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

6.  Abnormalities of the extracellular degradation of collagen type I in essential hypertension.

Authors:  C Laviades; N Varo; J Fernández; G Mayor; M J Gil; I Monreal; J Díez
Journal:  Circulation       Date:  1998-08-11       Impact factor: 29.690

Review 7.  Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms.

Authors:  K T Weber; Y Sun; S C Tyagi; J P Cleutjens
Journal:  J Mol Cell Cardiol       Date:  1994-03       Impact factor: 5.000

8.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.

Authors:  Y Y Li; A M Feldman; Y Sun; C F McTiernan
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

9.  Biochemical characterization of human collagenase-3.

Authors:  V Knäuper; C López-Otin; B Smith; G Knight; G Murphy
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

10.  Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin.

Authors:  H H Sigusch; S E Campbell; K T Weber
Journal:  Cardiovasc Res       Date:  1996-04       Impact factor: 10.787

View more
  5 in total

Review 1.  Fetal hypoxia and programming of matrix metalloproteinases.

Authors:  Wenni Tong; Lubo Zhang
Journal:  Drug Discov Today       Date:  2011-09-18       Impact factor: 7.851

Review 2.  Recent insights into cardiac hypertrophy and left ventricular remodeling.

Authors:  Risto Kerkela; Thomas Force
Journal:  Curr Heart Fail Rep       Date:  2006-04

Review 3.  Cardiac fibroblast: the renaissance cell.

Authors:  Colby A Souders; Stephanie L K Bowers; Troy A Baudino
Journal:  Circ Res       Date:  2009-12-04       Impact factor: 17.367

4.  Cardiac fibroblast-derived VCAM-1 enhances cardiomyocyte proliferation for fabrication of bioengineered cardiac tissue.

Authors:  Takahiro Iwamiya; Katsuhisa Matsuura; Shinako Masuda; Tatsuya Shimizu; Teruo Okano
Journal:  Regen Ther       Date:  2016-06-01       Impact factor: 3.419

5.  Human cardiac fibroblasts expressing VCAM1 improve heart function in postinfarct heart failure rat models by stimulating lymphangiogenesis.

Authors:  Takahiro Iwamiya; Bertrand-David Segard; Yuimi Matsuoka; Tomomi Imamura
Journal:  PLoS One       Date:  2020-09-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.